Jackson Grant Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Jackson Grant Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.94K	Hold	18	–	–	﹤0.01%	321
2026 Q1	$8.04K	Hold	18	–	–	﹤0.01%	317
2025 Q4	$8.16K	Hold	18	–	–	﹤0.01%	316
2025 Q3	$7.05K	Hold	18	–	–	﹤0.01%	321
2025 Q2	$8.01K	Hold	18	–	–	﹤0.01%	280
2025 Q1	$8.73K	Hold	18	–	–	﹤0.01%	271
2024 Q4	$7.25K	Hold	18	–	–	﹤0.01%	288
2024 Q3	$8.37K	Hold	18	–	–	﹤0.01%	277
2024 Q2	$8.44K	Hold	18	–	–	﹤0.01%	276
2024 Q1	$7.52K	Hold	18	–	–	﹤0.01%	271
2023 Q4	$7.32K	Hold	18	–	–	﹤0.01%	268
2023 Q3	$6.26K	Hold	18	–	–	﹤0.01%	274
2023 Q2	$6.33K	Hold	18	–	–	﹤0.01%	279
2023 Q1	$5.67K	Buy	+18	New	+$5.4K	﹤0.01%	316
2021 Q3	–	Sell	-67	Closed	-$14K	–	376
2021 Q2	$14K	Sell	67 -49	-42%	-$10.2K	0.01%	330
2021 Q1	$25K	Buy	+116	New	+$25.5K	0.01%	266

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Jackson Grant Investment Advisers's VRTX Position: Q2 2026 in Review

Jackson Grant Investment Advisers held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 18 shares worth $8.94K. The position accounts for ﹤0.01% of the portfolio, ranked #321.

Jackson Grant Investment Advisers first reported a position in VRTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $25K in Q1 2021. 733 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Jackson Grant Investment Advisers held 18 shares of Vertex Pharmaceuticals worth $8.94K as of Q2 2026.
Jackson Grant Investment Advisers left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Jackson Grant Investment Advisers's portfolio in Q2 2026, its #321 holding.
Jackson Grant Investment Advisers first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
Jackson Grant Investment Advisers's Vertex Pharmaceuticals position peaked at $25K in Q1 2021.
733 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Jackson Grant Investment Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.